Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H28N2O3 |
| Molecular Weight | 344.4479 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCCN=C1COC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=DUDKAZCAISNGQN-UHFFFAOYSA-N
InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3
| Molecular Formula | C20H28N2O3 |
| Molecular Weight | 344.4479 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB00383
Sources: https://www.drugbank.ca/drugs/DB00383
Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers. Daricon was discontinued in USA, but still used worldwide.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
9.2 null [pKi] | ||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
8.7 null [pKi] | ||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023 |
9.0 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DARICON Approved UseOxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg single, oral Highest studied dose |
unhealthy |
|
10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
5 mg single, intramuscular Studied dose Dose: 5 mg Route: intramuscular Route: single Dose: 5 mg Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. | 1992-09-01 |
|
| A LONG ACTING ANTICHOLINERGIC-SEDATIVE COMBINATION IN GASTROINTESTINAL DISORDERS. CLINICAL TRIAL OF OXYPHENCYCLIMINE HYDROCHLORIDE WITH PHENOBARBITAL (DARICON PB). | 1964-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14143029
In clinical trials oxyphencyclimine hydrochloride (5 mg) was prescribed daily, one tablet three times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1426023
[3H]NMS binding to M4 receptor was measured at 25°C in a total volume of 1.2 ml using the following incubation buffer: 50 mM sodium phosphate (pH 7.4) enriched with 2 mM MgCI2, 1% bovine serum albumin (except when indicated) and the indicated tracer and drug concentrations. In binding experiments on rat striatum ho-mogenates, the tracer concentration was 0.25 nM and the protein concentration 30-40 ug per assay (about 50 pM binding sites). Under equilibrium conditions (2 h incubation at 25°C) [3H]NMS labelled M,. M, and M4 sites in this brain region. To analyze tracer binding to M4 sites only, striatum homogenates were preincubated for 2 h at 25°C to allow equilibrium binding, then induced tracer dissociation by adding 1 uM atropine. [3H]NMS dissociated from its binding sites after 35 min of isotopic dilution, the residual binding being about 30% of initial binding. R-enantiomer of Oxyphencyclimine displaced binding of [3H]NMS to M4 receptors with pKi of 9.2, whereas binding of its S-enantiomer was less potent.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:27 GMT 2025
by
admin
on
Mon Mar 31 18:00:27 GMT 2025
|
| Record UNII |
4V44H1O8XI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A03AA01
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
||
|
WHO-VATC |
QA03AA01
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
||
|
WHO-ATC |
A03CA03
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
||
|
WHO-VATC |
QA03CA03
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
204-743-3
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
OXYPHENCYCLIMINE
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
32698
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
C100201
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
7256
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
m8342
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
4642
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
SUB09573MIG
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
100000083288
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
4V44H1O8XI
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
2026
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
125-53-1
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
DTXSID4023410
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
C66283
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
DB00383
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
839
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL1495
Created by
admin on Mon Mar 31 18:00:27 GMT 2025 , Edited by admin on Mon Mar 31 18:00:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |